Answer

IFF Scent recovery: drivers, 2H evolution (Fine Fragrance vs Consumer Fragrance), and the R&D plan to support 2027

1) Drivers of Scent’s recovery (what changed and why it’s improving)

A. Fine Fragrance: managing volatility from the Middle East and benefiting from strong/large prior-year comps

Management links Fine Fragrance’s recovery to active execution despite Middle East-related uncertainty, stating that the team “did a very good job at managing the challenges in the Middle East.” ¹
They also highlight that Fine Fragrance finished slightly positive vs expectations of mid-single-digit declines coming into the quarter. ¹
Even with continued crisis impacts, they are factoring “a softer Q3” and then expecting recovery starting into Q4, explicitly citing the large prior-year comp (Fine Fragrance grew ~20% in Q3 last year) as part of the year-over-year dynamics. ¹

B. Consumer Fragrance: rebuilding the go-to-market and R&D “capability,” driving market share

The recovery narrative for Consumer Fragrance emphasizes R&D capability rebuild and customer-facing go-to-market approach, tied to market share gains: management notes “the team has really done… a good job on the compounds, which is fine and consumer to rebuild the R&D capability go-to-market approach with customers, and trying to drive market share gains there.” ²
The performance mix for Scent in 1H 2026 supports the recovery: Scent segment sales were up 8%, and results were driven by double-digit growth in Fragrance Ingredients and high single-digit increase in Consumer Fragrance, with Fine Fragrance growing low single digits inclusive of Middle East impacts. ³
The company also ties segment profitability improvement to operational execution: Scent EBITDA grew 5% to $134 million, with “volume growth and productivity gains” described as primary drivers. ³

C. Fragrance Ingredients (within Scent): near-term rebound and then normalization toward higher-value ingredients

Scent’s near-term momentum is closely tied to Fragrance Ingredients strength: Fragrance Ingredients grew north of 20% in Q2, aided by tougher comps (comparing to a “down 10% or more” year-ago period). ¹
Management also says the team strategically leveraged the synthetics portfolio to capture sales amid macro/supply chain conditions including “higher Brent crude prices,” and expects the business to normalize as those conditions settle. ¹
The plan is for normalization to shift toward “higher value-added ingredients versus the traditional synthetics”; however, management clarifies this shift takes time and is not expected to be the dominant driver of 2H 2026—more so “as we go into next year and the year after.” ²

2) How Fine Fragrance and Consumer Fragrance will evolve in the second half of the year

Management provided explicit directional growth expectations for 2H 2026:

Fine Fragrance (2H trajectory)

Management expects Fine Fragrance to be “a little bit softer in Q3, but a stronger Q4.” ²
On a second-half basis, they frame Fine Fragrance growth as “mid-single-digit range,” and attribute this to continuing improvement on strong comparables. ²
They reiterate recovery timing consistent with the Middle East volatility and lapping dynamics: soft Q3, then recovery into Q4. ¹

Consumer Fragrance (2H trajectory)

Management expects Consumer Fragrance to be in the “low single-digit range.” ²
They contextualize this by noting Q2 was strong (high single-digit) and should “normalize” go-forward to low single-digit. ²
They also distinguish Consumer Fragrance from Fragrance Ingredients: Fragrance Ingredients is expected to be slightly under pressure due to normalization, while Consumer Fragrance is supported by rebuilt R&D capability and compounds/work with customers. ²

Summary view: 2H “directional mix” within Scent

Fine Fragrance: mid-single-digit 2H, softer Q3 and stronger Q4. ²
Consumer Fragrance: low single-digit 2H, normalizing from a high-single-digit Q2. ²
Fragrance Ingredients: “normalize” ongoing; management expects normalization and slight year-over-year pressure, while the structural shift to higher-value natural products plays out more into next year and the year after (not mainly 2H). ²

3) Plan for R&D to support 2027 (what’s being built and how it supports the next phase)

Management’s 2027 support plan is expressed in terms of pipeline health, capability rebuilding, and R&D investment as a competitive cycle—rather than as a single quantified budget in the excerpts provided.

A. R&D capability and pipeline strengthening is a key current “enabler”

Management describes the R&D pipeline as having materially improved: “2.5 years ago was not what it should have been” and “today… we’ve got a very strong R&D capability” with a “great pipeline of molecules as well as delivery systems.” ⁴
They also say this progress is embodied in “leading-edge new Fine Fragrances and Consumer Fragrances” developed by perfumers and supported by the stronger R&D team. ⁴

B. R&D is being used to drive the commercial recovery loop (market share + customer execution)

Management explicitly links R&D to market development and customer execution for Consumer Fragrance: rebuilding R&D capability and go-to-market approach with customers alongside compounds to drive market share gains. ²

C. R&D supports 2027 by reinforcing competitive positioning after near-term normalization

The company frames Fragrance Ingredients modernization (toward higher-value natural products) as underway but taking more time and having impact as we go into next year and the year after, i.e., the timeframe that would encompass 2027. ²
They also state that while some dynamics are expected to normalize in the near term (including compositional/environment effects), they believe the team will have a “really strong competitive position” as those changes flow through. ²

D. Investment and reinvestment are positioned as part of the “innovation matters” thesis

In the broader strategy discussion, management emphasizes continuing reinvestment in innovation/R&D as a “circle” where investments lead to better growth and margin, stating “innovation matters” and that critical reinvestment in R&D is important. ⁵

Bottom-line conclusions

Recovery drivers: Scent’s improvement is driven by (1) operational execution that mitigates Middle East volatility in Fine Fragrance, with timing dependent on Q3/Q4 comps, ¹ (2) Consumer Fragrance capability rebuild—especially R&D + compounds + customer go-to-market—to support market share gains, ² and (3) a near-term tailwind from Fragrance Ingredients growth that is expected to normalize and transition toward higher-value ingredients over time. ²¹
2H evolution: Fine Fragrance is expected to swing from a softer Q3 to a stronger Q4, producing mid-single-digit growth for the half; Consumer Fragrance should normalize to low single-digit for the half from a strong Q2. ²
R&D plan to support 2027: the company highlights strengthened R&D capability, pipeline depth (molecules + delivery systems), and product development progress (leading-edge Fine and Consumer Fragrances), while also using R&D to reinforce competitive positioning as higher-value ingredient and molecule/delivery-system initiatives mature into the next phase (including 2027). ⁴²

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

IFF Scent Recovery Driven by R&D, 2H 2026 Outlook and 2027 Plan

Sources used

Research question

Answer

IFF Scent recovery: drivers, 2H evolution (Fine Fragrance vs Consumer Fragrance), and the R&D plan to support 2027

1) Drivers of Scent’s recovery (what changed and why it’s improving)

2) How Fine Fragrance and Consumer Fragrance will evolve in the second half of the year

Fine Fragrance (2H trajectory)

Consumer Fragrance (2H trajectory)

Summary view: 2H “directional mix” within Scent

3) Plan for R&D to support 2027 (what’s being built and how it supports the next phase)

Bottom-line conclusions

References

Keep Reading

IFF's Scent Recovery Gains Momentum in 2H 2026 as R&D Drives 2027 Plan

Keep Reading

Keep Reading

IFF's Scent Recovery Gains Momentum in 2H 2026 as R&D Drives 2027 Plan

IFF Scent Recovery Driven by Operational Gains, Fragrance Strength, and 2027 R&D Plan

IFF Scent Recovery Driven by Ingredients Surge, 2H 2026 Outlook and 2027 R&D Plan

IFF Scent Recovery Gains Momentum in Q2, H2 Outlook, and 2027 R&D Plan

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF Scent Recovery Driven by R&D Rebuild; Q2 2026 H2 Outlook and 2027 Plan

IFF's Scent Recovery Q2 2026 Highlights, H2 Outlook and 2027 R&D Plan

IFF Scent Recovery Fueled by Q2 Strength, R&D Push, and 2027 Plan

IFF Signals Scent Recovery Driven by R&D Rebuild and 2027 Plan

IFF Scent Recovery Driven by R&D Rebuild, Fragrance Momentum, and 2027 Plan

IFF's Scent Recovery Driven by R&D Rebuild, 2027 Readiness Ahead

IFF Scent Recovery Driven by R&D Rebuild, H2 Outlook, and 2027 Plan